Study to Improve Renal Function After Kidney Transplantation

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by Angion Biomedica Corp
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Angion Biomedica Corp
ClinicalTrials.gov Identifier:
NCT01286727
First received: January 27, 2011
Last updated: October 6, 2014
Last verified: October 2014
  Purpose

The objective of the study is to evaluate the safety and activity of a investigational drug in improving renal function in patients who have undergone renal transplantation and have signs and symptoms of significant renal injury and are at risk for dialysis.


Condition Intervention Phase
Delayed Graft Function
Drug: BB3
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Multicenter Pilot Study of BB3 to Improve Renal Function in Patients With Signs and Symptoms of Significant Renal Injury After Kidney Transplantation and at Risk for Dialysis

Resource links provided by NLM:


Further study details as provided by Angion Biomedica Corp:

Primary Outcome Measures:
  • Urine production [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    mean time (days) until production of ≥ 50 cc/H of urine over a 12 hour period


Secondary Outcome Measures:
  • Change from baseline urine production [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Change from baseline urine production (cc/H) at each of the following time points: Day 3, Day 7, Day 14, and Day 28

  • creatinine clearance [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Mean measured 24-hour creatinine clearance at Days 3, 7, 14, and 28

  • Incidence of delayed graft function [ Time Frame: 7 days ] [ Designated as safety issue: No ]
    Incidence of delayed graft function (required dialysis due to inadequate renal function during the 7 days after transplantation)

  • Number of dialysis sessions [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Number of dialysis sessions through Day 7, 14, and 28

  • Daily urine output [ Time Frame: 14 days ] [ Designated as safety issue: No ]
    Mean total daily urine output through Day 14

  • Mean serum creatinine [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Mean serum creatinine at Days 4, 7, 10, 14, and 28

  • Number of acute rejection episodes [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Number of acute rejection episodes

  • Length of hospitalization following transplantation [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Length of hospitalization following transplantation

  • Biomarkers [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Comparison of biomarkers

  • adverse events, clinical laboratory evaluations, vital signs, ECG results [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]
    Safety assessments include adverse events, clinical laboratory evaluations, vital signs, ECG results.


Estimated Enrollment: 30
Study Start Date: January 2010
Estimated Study Completion Date: April 2015
Estimated Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Normal Saline
Placebo
Active Comparator: BB3 Drug: BB3
intravenous drug

Detailed Description:

Delayed graft function (DGF) is generally defined as the need for dialysis during the first 7 days after transplantation although the definition can also include failure to improve preexisting renal function. DGF is an important problem in renal allograft transplantation that affects approximately 25% of transplanted cadaveric kidneys. It has generally been observed that delayed graft function has been associated with reduced graft survival. In addition to an association of DGF with graft loss, DGF imposes an economic burden due to prolonged hospitalization and dialysis. The strongest association with occurrence of DGF is ischemia around the time of transplantation. Aside from approaches to minimize ischemia time and use of antibody induction, there are no good specific therapeutic options to prevent or treat delayed graft function. This study is designed to evaluate the safety and activity of an investigational drug in improving renal function in patients who have undergone renal transplantation and have signs and symptoms of significant renal injury and are at risk for dialysis.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males and females ≥ 18 years of age
  2. Had renal transplantation due to end stage disease requiring chronic dialysis
  3. Study drug can be administered within 36 hours after transplantation
  4. Received kidney from healthy donor or donor with history of diabetes mellitus or hypertension
  5. Donor terminal serum creatinine ≤ 2.2 mg/dL.
  6. No urine output, OR average urine output of < 50 cc/H over 8 or more consecutive hours, OR normal urine output following transplantation that diminished to average of < 50 cc/H over 8 or more consecutive hours, OR creatinine reduction ratio at 24 hours after transplantation to pre-transplantation is < 30%.
  7. Reason for low urine output is unlikely due to structural changes. If clinically indicated, an ultrasound will be performed
  8. Dry weight to< 120kg and BMI <35
  9. Women of child bearing potential have a negative serum pregnancy test prior to transplantation.
  10. Women of child bearing potential (including perimenopausal women who have had a menstrual period within 1 year) must agree to use 2 forms of effective birth control regimen (at least one-barrier method) during the 28-day study period. Men must agree to use condoms during the 28-day study period.
  11. In the opinion of the investigator, the subject is capable of understanding and complying with the protocol.
  12. Subjects must have signed the informed consent document prior to performance of any study related procedure including screening procedure.

Exclusion Criteria:

  1. Subject with normal urine output and not requiring dialysis prior to renal transplantation (i.e., had pre-emptive renal transplantation).
  2. Signs and symptoms of volume depletion.
  3. Recipient of multiple organ transplantation or scheduled for multiple organ transplantation.
  4. Recipient of pediatric en-bloc kidney transplantation.
  5. Recipient of kidney with cold ischemia time > 40 hours
  6. Has measurable donor-specific antibody or positive cross-match requiring deviation from standard immunosuppressive therapy.
  7. Currently participating in or has participated in an investigational drug or medical device study within 30 days or five half-lives, whichever is longer, prior to enrollment into this study.
  8. Concurrent sepsis or active bacterial infection.
  9. Have an active malignancy or history of solid, metastatic or hematologic malignancy with the exception of basal or squamous cell carcinoma of the skin that has been removed.
  10. Women of child bearing potential who are breast feeding.
  11. History of positive HIV test.
  12. History of rheumatoid arthritis.
  13. Subjects who require the cytochrome P450 1A2 (CYP1A2) inhibitors, ciprofloxacin and/or fluvoxamine (Luvox®)
  14. Subject is unwilling or unable to comply with the protocol or to cooperate fully with the Investigator or the site personnel.
  15. Subject is not deemed medically stable for the study in the opinion of the Investigator or the subject's primary nephrologist.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01286727

Contacts
Contact: Weizhong Cai, PhD 516-326-1200 wcai@angion.com
Contact: Itzhak D. Goldberg, MD, FACR 516-869-6400 igoldberg@angion.com

Locations
United States, California
California Institute of Renal Research Recruiting
San Diego, California, United States, 92123
Contact: Petrina Edwards, BS, CRC    858-637-4600    clorenzo@cairr.com   
Principal Investigator: Barry Brown, MD         
United States, District of Columbia
Medstar Georgetown University Hospital Recruiting
Washington, District of Columbia, United States, 20007
Contact: Marco Ertreo, MD    202-444-0652    Marco.Ertreo@gunet.georgetown.edu   
Contact: Kimiknu Mentore    202-444-1769    Kimiknu.Mentore@gunet.georgetown.edu   
Principal Investigator: Matthew Cooper, MD         
MedStar Washington Hospital Center Recruiting
Washington, District of Columbia, United States, 20010
Contact: Jessica A. Dinneen    202-374-9238    Jessica.Dinneen@medstar.net   
Principal Investigator: Matthew Cooper, MD         
United States, Maryland
Division of Transplant Surgery, University of Maryland School of Medicine, University of Maryland Medical Center Recruiting
Baltimore, Maryland, United States, 21201
Contact: Tiffany Saavedra, MHS    410-328-0303    TSaavedra@smail.umaryland.edu   
Contact: Minori Kinjo, MT(ASCP), Ph.D.    410-328-0303    mkinjo@smail.umaryland.edu   
Principal Investigator: Jonathan Bromberg, MD, PhD         
United States, New York
State University of New York at Buffalo Recruiting
Buffalo, New York, United States, 14215
Contact: Lin Feng    716-898-3418    lfeng@ecmc.edu   
Principal Investigator: Mark R. Laftavi, M.D, FACS         
United States, Texas
The Methodist Hospital Recruiting
Houston, Texas, United States, 77030
Contact: Sarah J Brann    (713) 441 6394    sjbrann@tmhs.org   
Principal Investigator: Osama Gaber, M.D., F.A.C.S., F.R.C.S.         
Sponsors and Collaborators
Angion Biomedica Corp
Investigators
Study Director: Weizhong Cai, PhD Sponsor GmbH
  More Information

No publications provided

Responsible Party: Angion Biomedica Corp
ClinicalTrials.gov Identifier: NCT01286727     History of Changes
Other Study ID Numbers: 001-09, 2R44DK066654
Study First Received: January 27, 2011
Last Updated: October 6, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Delayed Graft Function
Pathologic Processes

ClinicalTrials.gov processed this record on October 19, 2014